Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: A French nationwide study


      • We analyzed 37 cases of rituximab induced serum sickness (RISS).
      • RISS occurred mainly after the first injection of rituximab.
      • RISS was significantly more frequent during autoimmune diseases, especially Lupus.



      Rituximab induced serum sickness (RISS) is a rare delayed hypersensitivity reaction. The aim of this study was to describe the epidemiological and clinical characteristics of the RISS cases reported in France.


      Serum sickness cases involving rituximab were identified from the French PharmacoVigilance Database from 1998 to 2016.


      We analyzed 37 cases of RISS. Rituximab was prescribed for an autoimmune disease in 78% of cases. Serum sickness occurred mainly after the first injection (54%) with a median time to onset of 12 days. The most frequent manifestations were rheumatologic symptoms (92%), fever (87%), and skin lesions (78%). The incidence was significantly higher when rituximab was used for autoimmune diseases than for a hematological malignancies. Taking into account the existence of a Systemic Lupus Erythematosus (SLE) as the indication of rituximab or as a comorbidity, the incidence of RISS in patients with SLE was even higher.


      We report on the largest series of RISS studied to date and confirm that this reaction preferentially occurs in patients with autoimmune disease, especially SLE. This may be due to B-cell lysis, leading to the release of intracellular antigens into the serum and subsequent antigen-antibody complex formation, especially in patients with elevated autoantibody production. This could also explain why RISS often occurred after a single injection.


      Patients generally recovered from RISS rapidly without obvious benefit from corticosteroid therapy. The risk of recurrence should prompt clinicians to question the use of rituximab after an episode of RISS.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bennett C.M.
        • Rogers Z.R.
        • Bussel J.B.
        • et al.
        Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura.
        Blood. 2006; 107: 2639-2642
        • Meijer J.M.
        • Vissink A.
        • et al.
        Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.
        Arthritis Rheum. 2010; 62: 960-968
        • Zaja F.
        • De Vita S.
        • Mazzaro C.
        • et al.
        Efficacy and safety of rituximab in type II mixed cryoglobulinemia.
        Blood. 2003; 101: 3827-3834
        • Joly P.
        • Mouquet H.
        • Roujeau J.C.
        • D'Incan M.
        • Gilbert D.
        • Jacquot S.
        • et al.
        A single cycle of rituximab for the treatment of severe pemphigus.
        N Engl J Med. 2007; 357: 545-552
        • Dahan K.
        • Debiec H.
        • Rousseau A.
        • et al.
        Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up.
        J Am Soc Nephrol. 2017; 28: 348-358
        • Gottenberg J.-E.
        • Guillevin L.
        • Lambotte O.
        • et al.
        Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
        Ann Rheum Dis. 2005; 64: 913-920
        • Winkler U.
        • Jensen M.
        • Manzke H.
        • et al.
        Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).
        Blood. 1999; 94: 2217-2224
        • Cheungpasitporn W.
        • Kopecky S.L.
        • Specks U.
        Bharucha, et al. non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy.
        J Renal Inj Prev. 2017; 6: 18-25
        • Kimby E.
        Tolerability and safety of rituximab (MabThera).
        Cancer Treat Rev. 2005; 31: 456-473
        • Succaria F.
        • Sahni D.
        • Wolpowitz D.
        Rituximab-induced serum sickness–like reaction: a histopathologic viewpoint.
        Am J Dermatopathol. 2016; 38: 321-322
        • Hester C.G.
        Immune complex–mediated diseases.
        in: Frank M.M. Adkinson Jr., N.F. Bochner B.S. Burks W. Middleton's allergy principles and practice. 8th ed. Saunders, Philadelphia PA2014: 602-616
        • Lawley T.J.
        • Bielory L.
        • Gascon P.
        • Yancey K.B.
        • Young N.S.
        • Frank M.M.
        A prospective clinical and immunologic analysis of patients with serum sickness.
        N Engl J Med. 1984; 311: 1407-1413
        • Heckbert S.R.
        • Stryker W.S.
        • et al.
        Serum sickness in children after antibiotic exposure: estimates of occurrence and morbidity in a health maintenance organization population.
        Am J Epidemiol. 1990; 132: 336-342
        • D'Arcy C.A.
        • Mannik M.
        Serum sickness secondary to treatment with the murine–human chimeric antibody IDEC-C2B8 (rituximab).
        Arthritis Rheum. 2001; 44: 1717-1718
        • Karmacharya P.
        • Poudel D.R.
        • Pathak R.
        • Donato A.A.
        • Ghimire S.
        • Giri S.
        • et al.
        Rituximab-induced serum sickness: a systematic review.
        Semin Arthritis Rheum. 2015; 45: 334-340
        • Moore N.
        • Noblet C.
        • Kreft-Jais C.
        • Lagier G.
        • et al.
        French pharmacovigilance database system: examples of utilization.
        Therapie. 1995; 50: 557-562
        • Faisandier L.
        • Fouillet A.
        • Bringay S.
        • et al.
        Surveillance and detection of unusual events in toxicovigilance: review of relevant methods.
        Rev Epidemiol Sante Publique. 2015; 63: 119-131
        • Lindquist M.
        • Edwards I.R.
        The WHO Programme for international drug monitoring, its database, and the technical support of the Uppsala monitoring center.
        J Rheumatol. 2001; 28: 1180-1187
        • Seror R.
        • Sordet C.
        • Guillevin L.
        • Hachulla E.
        • Masson C.
        • et al.
        Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.
        Ann Rheum Dis. 2007; 66: 351-357
        • Pijpe J.
        • van Imhoff G.W.
        • Spijkervet F.K.
        • Mansour K.
        • et al.
        Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.
        Arthritis Rheum. 2005; 52: 2740-2750
        • Dass S.
        • Bowman S.J.
        • et al.
        Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.
        Ann Rheum Dis. 2008; 67: 1541-1544
        • Devauchelle-Pensec V.
        • Pennec Y.
        • Morvan J.
        • et al.
        Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20).
        Arthritis Rheum. 2007; 57: 310-317
        • Wang J.
        • Wiley J.M.
        • Luddy R.
        • Bussel J.B.
        • et al.
        Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment.
        J Pediatr. 2005; 146: 217-221
        • Sène D.
        • Amoura Z.
        • Cacoub P.
        • et al.
        Rituximab may form a complex with IgMκ mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis.
        Arthritis Rheum. 2009; 60: 3848-3855
        • Merrill J.T.
        • Neuwelt C.M.
        • Latinis K.M.
        • et al.
        Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.
        Arthritis Rheum. 2010; 62: 222-233
        • Finger E.
        • Scheinberg M.
        Development of serum sickness-like symptoms after rituximab infusion in two patients with severe hypergammaglobulinemia.
        J Clin Rheumatol. 2007; 13: 94-95
        • Le Guenno G.
        • Ruivard M.
        • Charra L.
        • Philippe P.
        Rituximab-induced serum sickness in refractory immune thrombocytopenic purpura.
        Intern Med J. 2011; 41: 202-205
        • Goto S.
        • Goto H.
        • Sekiguchi O.
        • et al.
        Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura.
        Int J Hematol. 2009; 89: 305-309
        • Schmidt E.
        • Hennig K.
        • Mengede C.
        • Zillikens D.
        • Kromminga A.
        Immunogenicity of rituximab in patients with severe pemphigus.
        Clin Immunol. 2009; 132: 334-341
        • Grillo-Lopez A.J.
        • White C.A.
        • Varns C.
        • Shen D.
        • Wei A.
        • McClure A.
        • et al.
        Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
        Semin Oncol. 1999; 26: 66-73
        • Looney R.J.
        • Anolik J.H.
        • Arend L.J.
        • et al.
        B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.
        Arthritis Rheum. 2004; 50: 2580-2589
        • Edwards J.C.
        • SzczepanskiI L.
        • Szechinski J.
        • et al.
        Efficacy of B-cells-targeted therapy with rituximab in patients with rheumatoid arthritis.
        N Engl J Med. 2004; 350: 2572-2581
        • Todd D.
        • Helfgott S.
        Serum sickness following treatment with rituximab.
        J Rheumatol. 2007; 34: 430-433
        • Mehsen N.
        • Yvon C.M.
        • Richez C.
        • Schaeverbeke T.
        Serum sickness following a first rituximab infusion with no recurrence after the second one.
        Clin Exp Rheumatol. 2008; 26: 967
        • Ungprasert P.
        • Srivali N.
        • et al.
        Rituximab-induced serum sickness in overlapping syndrome between Sjögren syndrome and systemic lupus erythematosus.
        J Clin Rheumatol. 2013; 19: 360
        • Erffmeyer J.E.
        Serum sickness.
        Ann Allergy. 1986; 56: 105-109
        • Manko A.
        • Besecker B.
        Plasmapheresis reverses ARDS in rituximab induced serum sickness.
        Chest. 2014; 146: 269
        • Fajt M.L.
        • Petrov A.A.
        Desensitization protocol for rituximab-induced serum sickness.
        Curr Drug Saf. 2014; 9: 240-242
        • Albert D.
        • Dunham J.
        • Khan S.
        • Stansberry J.
        • et al.
        Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.
        Ann Rheum Dis. 2008; 67: 1724-1731
        • Looney R.J.
        • Anolik J.H.
        • Felgar R.E.
        • et al.
        B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.
        Arthritis Rheum. 2004; 50: 2580-2589
        • Lunardon L.
        • Payne A.
        Inhibitory human anti-chimeric antibodies to rituximab in a pemphigus patient.
        J Allergy Clin Immunol. 2012; 130: 800-803
        • Schmidt E.
        • Hennig K.
        • Mengede C.
        • Zillikens D.
        • Kromminga A.
        Immunogenicity of rituximab in patients with severe pemphigus.
        Clin Immunol. 2009; 132: 334-341